A biotechnology company that develops medicines to treat degenerative muscle diseases, utilizing its proprietary MyoReGenX platform for automated microscopy and muscle stem cell research. The company is developing SAT-3247, an oral small-molecule drug candidate for treating Duchenne muscular dystrophy.